Matches in SemOpenAlex for { <https://semopenalex.org/work/W3004438563> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W3004438563 endingPage "120" @default.
- W3004438563 startingPage "120" @default.
- W3004438563 abstract "120 Background: Irinotecan (IRI) toxicity was worse in female (F) than in male (M) patients (pts) on FOLFIRI for metastatic colorectal cancer (MCC). This finding could reflect different optimal administration timing of IRI in M and F pts along the 24 hours. IRI pharmacology is regulated by the circadian clock, and its least toxic daily time (LTT) occurred ~6 hours later in F as compared to M mice. The relevance of sex for the LTT of IRI is addressed here using data from an international randomized trial, whose primary endpoint was not met for all the 193 pts with MCC (EORTC 05011). Methods: 130 M and 63 F were randomized to receive chronomodulated IRI (180 mg/m2 over 6-h, with peak delivery in the morning (at 5:00 or 9:00), in the afternoon (at 13:00 or 17:00) or at night (at 21:00 or 01:00) on day (d) 1, followed by fixed-time chronomodulated oxaliplatin-5-fluorouracil-leucovorin for 4 d. Triplet combination was given q3 weeks as 1st or 2nd line, without prophylactic G-CSF. The relevance of IRI timing for main toxicities was determined separately in M and F, using Cosinor and Fisher Exact tests. Results: Baseline characteristics of M or F pts did not differ significantly according to IRI timing group. Main worse grade 3-4 toxicities per pt after 6 courses were diarrhea (M, 40.2%; F, 51.9%) neutropenia (M, 12.6%; F, 18.4%), fatigue (M, 13.4%; F, 17.3%) and anorexia (M, 8.2%; F, 9.6%). These toxicities were reduced following IRI delivery in the morning for M, but in the afternoon for F, with statistically significant rhythms (p < 0.05 from cosinor) and sex*timing interactions (Fischer Exact, diarrhea, p = 0.023; neutropenia, p = 0.015; fatigue, p = 0.062; anorexia, p = 0.032). IRI timing was most critical for F, with Grade 3-4 toxicities ranging from 55.2% of the pts (morning) to 29.4% (afternoon) for diarrhea, and from 25.9% (morning) to 0% (afternoon) for neutropenia. IRI timing did not significantly influence efficacy. Conclusions: The present study results supports the administration of irinotecan in the morning for M and in the afternoon for F in order to minimize adverse events of triplet chemotherapy without impairing efficacy. Prospective trials testing sex specific timing issues are warranted. Clinical trial information: 05011." @default.
- W3004438563 created "2020-02-14" @default.
- W3004438563 creator A5000057889 @default.
- W3004438563 creator A5000726989 @default.
- W3004438563 creator A5012325306 @default.
- W3004438563 creator A5019631884 @default.
- W3004438563 creator A5022909423 @default.
- W3004438563 creator A5037937397 @default.
- W3004438563 creator A5060428508 @default.
- W3004438563 creator A5065770398 @default.
- W3004438563 creator A5077857574 @default.
- W3004438563 creator A5078259466 @default.
- W3004438563 date "2020-02-01" @default.
- W3004438563 modified "2023-10-18" @default.
- W3004438563 title "Optimizing FOLFIRINOX tolerability in patients with colorectal cancer through dosing irinotecan in the morning for men and in the afternoon for women." @default.
- W3004438563 doi "https://doi.org/10.1200/jco.2020.38.4_suppl.120" @default.
- W3004438563 hasPublicationYear "2020" @default.
- W3004438563 type Work @default.
- W3004438563 sameAs 3004438563 @default.
- W3004438563 citedByCount "2" @default.
- W3004438563 countsByYear W30044385632020 @default.
- W3004438563 countsByYear W30044385632023 @default.
- W3004438563 crossrefType "journal-article" @default.
- W3004438563 hasAuthorship W3004438563A5000057889 @default.
- W3004438563 hasAuthorship W3004438563A5000726989 @default.
- W3004438563 hasAuthorship W3004438563A5012325306 @default.
- W3004438563 hasAuthorship W3004438563A5019631884 @default.
- W3004438563 hasAuthorship W3004438563A5022909423 @default.
- W3004438563 hasAuthorship W3004438563A5037937397 @default.
- W3004438563 hasAuthorship W3004438563A5060428508 @default.
- W3004438563 hasAuthorship W3004438563A5065770398 @default.
- W3004438563 hasAuthorship W3004438563A5077857574 @default.
- W3004438563 hasAuthorship W3004438563A5078259466 @default.
- W3004438563 hasConcept C121608353 @default.
- W3004438563 hasConcept C126322002 @default.
- W3004438563 hasConcept C143998085 @default.
- W3004438563 hasConcept C168563851 @default.
- W3004438563 hasConcept C19720800 @default.
- W3004438563 hasConcept C197934379 @default.
- W3004438563 hasConcept C203092338 @default.
- W3004438563 hasConcept C2777063308 @default.
- W3004438563 hasConcept C2777288759 @default.
- W3004438563 hasConcept C2778375690 @default.
- W3004438563 hasConcept C2780259306 @default.
- W3004438563 hasConcept C2780456651 @default.
- W3004438563 hasConcept C2780962732 @default.
- W3004438563 hasConcept C29730261 @default.
- W3004438563 hasConcept C526805850 @default.
- W3004438563 hasConcept C71924100 @default.
- W3004438563 hasConcept C90924648 @default.
- W3004438563 hasConceptScore W3004438563C121608353 @default.
- W3004438563 hasConceptScore W3004438563C126322002 @default.
- W3004438563 hasConceptScore W3004438563C143998085 @default.
- W3004438563 hasConceptScore W3004438563C168563851 @default.
- W3004438563 hasConceptScore W3004438563C19720800 @default.
- W3004438563 hasConceptScore W3004438563C197934379 @default.
- W3004438563 hasConceptScore W3004438563C203092338 @default.
- W3004438563 hasConceptScore W3004438563C2777063308 @default.
- W3004438563 hasConceptScore W3004438563C2777288759 @default.
- W3004438563 hasConceptScore W3004438563C2778375690 @default.
- W3004438563 hasConceptScore W3004438563C2780259306 @default.
- W3004438563 hasConceptScore W3004438563C2780456651 @default.
- W3004438563 hasConceptScore W3004438563C2780962732 @default.
- W3004438563 hasConceptScore W3004438563C29730261 @default.
- W3004438563 hasConceptScore W3004438563C526805850 @default.
- W3004438563 hasConceptScore W3004438563C71924100 @default.
- W3004438563 hasConceptScore W3004438563C90924648 @default.
- W3004438563 hasIssue "4_suppl" @default.
- W3004438563 hasLocation W30044385631 @default.
- W3004438563 hasOpenAccess W3004438563 @default.
- W3004438563 hasPrimaryLocation W30044385631 @default.
- W3004438563 hasRelatedWork W1999941843 @default.
- W3004438563 hasRelatedWork W2039734044 @default.
- W3004438563 hasRelatedWork W2069668461 @default.
- W3004438563 hasRelatedWork W2093069512 @default.
- W3004438563 hasRelatedWork W2127084143 @default.
- W3004438563 hasRelatedWork W2347320353 @default.
- W3004438563 hasRelatedWork W2363674970 @default.
- W3004438563 hasRelatedWork W2766409029 @default.
- W3004438563 hasRelatedWork W349909140 @default.
- W3004438563 hasRelatedWork W4251645124 @default.
- W3004438563 hasVolume "38" @default.
- W3004438563 isParatext "false" @default.
- W3004438563 isRetracted "false" @default.
- W3004438563 magId "3004438563" @default.
- W3004438563 workType "article" @default.